Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Oxon Hill, Maryland Clinical Trials

A listing of Oxon Hill, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (797) clinical trials

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Phase

0.0 miles

Learn More »

Lyme Test Indication Combinations (LyTIC) Study

The present study aims to investigate the performance characteristics of both established and new assays for Borrelia burgdorferi infection and to assess the relative performance of appropriate combinations of these tests. The study will also investigate the effect of the time course of the infection and its treatment on the ...

Phase N/A

0.0 miles

Learn More »

Effect of Efpeglenatide on Cardiovascular Outcomes in High Cardiovascular Risk Type 2 Diabetes Patients

The estimated study duration per participant is up to approximately 36 months.

Phase

0.0 miles

Learn More »

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing. Once-daily triple therapy of an Inhaled Corticosteroid/ Long-acting Muscarinic Receptor Antagonists/ Long Acting Beta-Agonist (ICS/LAMA/LABA) that is combination of FF/UMEC/VI in a single ...

Phase

0.52 miles

Learn More »

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old

In pediatric Type 2 Diabetes Mellitus (T2DM) subjects on diet and exercise and metformin, or insulin, or metformin and insulin: The primary research hypothesis for dapagliflozin is whether addition of dapagliflozin, including up-titration if needed, results in a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) as compared to ...

Phase

1.67 miles

Learn More »

The STAR Tumor Ablation Registry

The STAR Prospective Registry is an observational registry to gather clinical safety and outcome data in patients with painful spinal metastases in the thoracolumbar spine (T1-L5) following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.

Phase N/A

3.1 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the correction of anemia and maintenance of Hb in subjects with NDD-CKD

Phase

3.1 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with NDD-CKD

Phase

3.1 miles

Learn More »

28mm Ceramic-on-Ceramic Total Hip Replacement Study

This is a prospective, non-randomized study of the 28mm Ceramic on Ceramic (COC) device. This study will follow each subject through 10 years postoperatively and will consist of: a clinical follow-up phase and a clinical outcomes phase. Radiographic and clinical follow-up exams will take place at six-weeks, six-months and then ...

Phase N/A

3.1 miles

Learn More »

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

Specific Aims BRCA1/2 mutations are the most commonly identified Hereditary Breast and Ovarian Cancer (HBOC) mutations. Women with these mutations have a 50-80% lifetime risk of developing breast cancer. Breast cancer survivors with a BRCA1/2 mutation are at higher risk of developing contralateral breast cancer than survivors without mutations. The ...

Phase N/A

3.36 miles

Learn More »